Gsk (GSK) Other Working Capital Changes (2009 - 2026)

Gsk (GSK) has 18 years of Other Working Capital Changes data on file, last reported at -$1.5 billion in Q3 2026.

• For the quarter ending Q3 2026, Other Working Capital Changes changed N/A year-over-year to -$1.5 billion; the trailing twelve-month figure through Sep 2026 stood at -$5.6 billion (changed N/A YoY), and the FY2025 full-year result was -$827.4 million, down 269.86% from the prior year.
• Other Working Capital Changes was -$1.5 billion for Q3 2026 at Gsk, down from -$1.5 billion in the prior quarter.
• In the past five years, Other Working Capital Changes ranged from a high of -$232.2 million in Q4 2022 to a low of -$1.7 billion in Q4 2025.
• A 5-year average of -$1.1 billion and a median of -$1.1 billion in 2023 frame the typical range for Other Working Capital Changes.
• Across the five-year window, Other Working Capital Changes soared 78.7% in 2022 and tumbled 561.09% in 2023, its largest moves.
• Gsk's Other Working Capital Changes stood at -$232.2 million in 2022, then tumbled by 561.09% to -$1.5 billion in 2023, then grew by 20.16% to -$1.2 billion in 2024, then tumbled by 35.97% to -$1.7 billion in 2025, then increased by 11.55% to -$1.5 billion in 2026.
• Per Business Quant data, the three most recent Other Working Capital Changes figures were -$1.5 billion in Q3 2026, -$1.5 billion in Q1 2026, and -$1.7 billion in Q4 2025.